Cargando…

Adjuvant-dependent cytokine profiles in the context of a DNA prime-protein boost HIV-1 vaccine

Detalles Bibliográficos
Autores principales:	Buglione-Corbett, R, Pouliot, K, Marty-Roix, R, West, K, Wang, S, Lien, E, Lu, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441842/ http://dx.doi.org/10.1186/1742-4690-9-S2-P16

Ejemplares similares

Serum Cytokine Profiles Associated with Specific Adjuvants Used in a DNA Prime-Protein Boost Vaccination Strategy
por: Buglione-Corbett, Rachel, et al.
Publicado: (2013)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

Macaques primed with self-amplifying RNA vaccines expressing HIV-1 envelope and boosted with recombinant protein show potent T- and B-cell responses
por: Bogers, WM, et al.
Publicado: (2012)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

SIVconsv DNA prime - TLR7/IFNα adjuvanted long peptide boost induces potent CD4+ Ab responses and protects against high dose intrarectal SIV challenge
por: Koopman, G, et al.
Publicado: (2012)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
por: Stutz, H, et al.
Publicado: (2009)

P04-24. Frequencies of HIV Env-specific B cells and neutralizing antibodies during DNA-prime/protein-boost immunization with three different Env immunogens*
por: Tawde, P, et al.
Publicado: (2009)

P11-06. Intravaginal administration of HIV-1ZM96 gp140 augments systemic and mucosal antibody responses following systemic priming with adjuvanted protein
por: Cranage, M, et al.
Publicado: (2009)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012)

Protection against highly pathogenic SIV by BCG-SIV recombinant priming and attenuated replicating vaccinia-SIV recombinant boosting
por: Zhang, X, et al.
Publicado: (2012)

A prime-boost immunization with rBCG expressing HIV-1 Gag, RT and gp120 and SAAVI MVA-C elicits immune responses in blood and MALT of rhesus macaques
por: Chege, GK, et al.
Publicado: (2012)

E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost
por: Hutnick, NA, et al.
Publicado: (2012)

Hyperglycosylated gp120 mutants elicit improved CD4-binding site directed antibodies in a heterologous prime:boost regimen
por: Ahmed, FK, et al.
Publicado: (2012)

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates
por: Chakrabarti, BK, et al.
Publicado: (2012)

P02-04. Multimeric soluble CD40 ligand efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus strains
por: Najera, J, et al.
Publicado: (2009)

P19-37. Replication-defective lymphocytic choriomeningitis virus vectors boost cellular and humoral immunity after DNA or adenovirus vector priming
por: Flatz, LR, et al.
Publicado: (2009)

Recombinant attenuated M.tuberculosis-SIVgag(rAMtb-gag) vaccination primes for SIV-specific CD8 T cell response that are boosted by Ad5-SIVgag in mice
por: Kadayam Ranganathan, U, et al.
Publicado: (2012)

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
por: Cingolani, A, et al.
Publicado: (2010)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
por: Kaewkungwal, J, et al.
Publicado: (2009)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Synergistic DNA-adenovirus prime-boost immunization eliminates metastatic colorectal cancer by inducing high avidity effector CD8+ T cells
por: Xiang, Bo, et al.
Publicado: (2014)

P17-10. A new AuxoGTU-HIV B DNA vaccine induce very long lasting HIV specific T cells response which is efficiently boosted with HIV LAI lipopeptides
por: Mangeot-Méderlé, I, et al.
Publicado: (2009)

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
por: O'Connell, RJ, et al.
Publicado: (2012)

A single dose of SAAVI MVA-C reboosts rhesus macaques after more than 3 years post DNA-MVA prime-boost vaccination
por: Chege, GK, et al.
Publicado: (2012)

P19-55 LB. Effective control of a pathogenic SIVmac239 challenge by a novel heterologous mucosal prime and intramuscular boost vaccine strategy
por: Chen, Z, et al.
Publicado: (2009)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

P19-07. Development of a protective HIV/SIV vaccine based on a self-boosting cytomegalovirus vector
por: Ambagala, A, et al.
Publicado: (2009)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Identification of differential pharyngeal cytokine profiles during HIV infection
por: Perera, RAPM, et al.
Publicado: (2011)

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
por: Avihingsanon, A, et al.
Publicado: (2010)

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
por: Bakari, M, et al.
Publicado: (2009)

Plasma cytokine levels and HIV-specific immune responses during acute/early HIV infection
por: Turk, G, et al.
Publicado: (2012)

Procalcitonin, cytokine and NOx in diabetic ketoacidosis
por: Suwarto, S, et al.
Publicado: (2008)

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost
por: Apostólico, Juliana de Souza, et al.
Publicado: (2016)

A new method for integrated analysis applied to gene expression and cytokines secretion in response to LIPO-5 vaccine in HIV-negative volunteers
por: Thiebaut, R, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ig0hoq1itrhl7qnn4b4er4ed7p